NEPHROS INC - Common Stock - $0.001 par value (NEPH)

CUSIP: 640671400

Q4 2023 13F Holders as of 31 Dec 2023

Type / Class
Equity / Common Stock - $0.001 par value
Shares outstanding
10,630,964
Total 13F shares
4,331,833
Share change
+42,873
Total reported value
$14,986,626
Price per share
$3.46
Number of holders
18
Value change
+$148,381
Number of buys
10
Number of sells
2

Security key

640671400

Report period

Q4 2023

Institutions

18

Top holders

10

Top shareholders of NEPH - NEPHROS INC - Common Stock - $0.001 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
WEXFORD CAPITAL LP
13F
Company
35%
3,687,438
$5,457,408 30 Sep 2023
13F
BARD ASSOCIATES INC
13F
Company
1.7%
186,039
$275,338 30 Sep 2023
13F
VANGUARD GROUP INC
13F
Company
1.6%
170,712
$252,654 30 Sep 2023
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.67%
71,037
$106,228 30 Sep 2023
13F
HighTower Advisors, LLC
13F
Company
0.53%
56,710
$83,000 30 Sep 2023
13F
ELKHORN PARTNERS LIMITED PARTNERSHIP
13F
Company
0.43%
45,341
$67,000 30 Sep 2023
13F
BLAIR WILLIAM & CO/IL
13F
Company
0.34%
36,249
$53,649 30 Sep 2023
13F
STATE STREET CORP
13F
Company
0.15%
15,698
$23,469 30 Sep 2023
13F
MORGAN STANLEY
13F
Company
0.14%
15,292
$22,632 30 Sep 2023
13F
BlackRock Finance, Inc.
13F
Company
0.04%
4,131
$6,114 30 Sep 2023
13F
Tower Research Capital LLC (TRC)
13F
Company
0%
226
$334 30 Sep 2023
13F
WELLS FARGO & COMPANY/MN
13F
Company
0%
68
$101 30 Sep 2023
13F
UBS Group AG
13F
Company
0%
11
$16 30 Sep 2023
13F
JPMORGAN CHASE & CO
13F
Company
0%
8
$12 30 Sep 2023
13F
Daron Evans
3/4/5
CEO Specialty Renal Products
mixed-class rows
179,718
mixed-class rows
$351,795 24 May 2021
Andrew Astor Power
3/4/5
President, CEO & CFO, Director
mixed-class rows
131,385
mixed-class rows
$204,342 05 Mar 2022
Tom Gwydir Power
3/4/5
Director
mixed-class rows
50,306
mixed-class rows
$95,210 05 Jan 2023
Wesley S. Lobo
3/4/5
Chief Marketing Officer
mixed-class rows
206,714
mixed-class rows
$77,461 16 Feb 2022

Institutional Holders of NEPHROS INC - Common Stock - $0.001 par value (NEPH) as of Q4 2023

As of 31 Dec 2023, NEPHROS INC - Common Stock - $0.001 par value (NEPH) was held by 18 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 4,331,833 shares. The largest 10 holders included WEXFORD CAPITAL LP, BARD ASSOCIATES INC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, HighTower Advisors, LLC, BLAIR WILLIAM & CO/IL, MORGAN STANLEY, ELKHORN PARTNERS LIMITED PARTNERSHIP, STATE STREET CORP, and Mesirow Financial Investment Management, Inc.. This page lists 18 institutional shareholders reporting positions in this security for the Q4 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q4 2023 vs Q3 2023 Across Filers

Q3 2023 holders
14
Q4 2023 holders
18
Holder diff
4
Investor Q3 2023 Shares Q4 2023 Shares Share Diff Share Chg % Q3 2023 Value $ Q4 2023 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .